文献速递肾小球疾病

利妥昔单抗治疗成人膜性肾病的长期结局

Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.
PubMed 文献 · Kidney Int Rep · 2025-05-21

这项回顾性研究纳入2000年1月至2022年12月接受利妥昔单抗治疗的159例膜性肾病患者,评估终末期肾病和eGFR下降>50%等硬终点。88.1%的患者达到完全或部分缓解,中位随访62.6个月时4.4%进展至终末期肾病,5年和10年肾脏生存率分别为97%和95.4%。

要点

  • 159例接受利妥昔单抗治疗的膜性肾病患者中,88.1%达到完全或部分缓解。
  • 中位随访62.6个月,7例(4.4%)进展至终末期肾病,5年和10年肾脏生存率分别为97%和95.4%。
  • 既往免疫抑制治疗和间质纤维化/肾小管萎缩≥25%是与利妥昔单抗无应答相关的独立因素。

核心结论

  • 利妥昔单抗治疗与良好的长期肾脏生存相关,优于历史对照的环磷酰胺/糖皮质激素周期方案生存率。

研究设计与样本

  • 回顾性研究,纳入2000年1月至2022年12月期间接受利妥昔单抗治疗的所有膜性肾病患者,共159例(75.5%男性,87.4%白人,中位年龄58岁)。

主要发现

  • 140/159例(88.1%)达到完全或部分缓解,达到完全缓解和部分缓解的中位时间分别为22.6(15.5-37.4)个月和6.8(3.6-12.1)个月。
  • 11.9%的患者对利妥昔单抗无应答,既往免疫抑制治疗和间质纤维化/肾小管萎缩≥25%是与无应答相关的独立因素。
  • 中位随访62.6个月,7/159例(4.4%)发生终末期肾病,5年和10年估计肾脏生存率分别为97%(95%CI:94%-100%)和95.4%(95%CI:91.2%-99%)。

关键数值与推荐

  • 完全缓解、部分缓解(基线蛋白尿下降≥50%且蛋白尿≤3.5 g/24 h)和免疫学缓解(血清抗磷脂酶A2受体抗体[PLA2R-Ab]清除)为临床结局指标。
  • 108例(75.5%)为PLA2R-Ab相关膜性肾病(PLA2R-MN)。
  • 基线血清肌酐1.50(1.1-1.9)mg/dl,eGFR 54.6(37.4-72.5)ml/min/1.73 m²,蛋白尿9.2(6.7-11.9)g/24 h,血清白蛋白2.7(2.2-3.2)g/dl。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rituximab (RTX) therapy has become the standard of care for treatment of membranous nephropathy (MN). However, data on hard outcomes such as end-stage kidney disease (ESKD) and loss of estimated glomerular filtration rate (eGFR), are lacking. METHODS: This was a retrospective study on all patients with MN treated with RTX between January 2000 and December 2022. The primary outcomes were ESKD and eGFR loss > 50%. Clinical outcomes were complete remission (CR), partial remission (PR) (reduction in baseline proteinuria ≥ 50% and proteinuria ≤ 3.5 g/24 h), and immunological remission (IR) (serum antiphospholipase A receptor antibody [PLA2R-Ab] depletion). RESULTS: A total of 159 patients were included (75.5% male, 87.4% White, median age: 58 years); 52.8% had previous immunosuppression (IS). Baseline serum creatinine was 1.50 (1.1-1.9) mg/dl, eGFR was 54.6 (37.4-72.5) ml/min per 1.73 m2, proteinuria was 9.2 (6.7-11.9) g/24 h, and serum albumin was 2.7 (2.2-3.2) g/dl; Of the patients, 108 (75.5%) had PLA2R-Ab-associated MN (PLA2R-MN); and 140 of 159 (88.1%) attained CR or PR. Median (interquartile range [IQR]) time to CR and PR were 22.6 (15.5-37.4) and 6.8 (3.6-12.1) months, respectively. Failure to respond to RTX was observed in 11.9% of patients. Previous IS and interstitial fibrosis/tubular atrophy (IFTA) ≥ 25% were independent factors associated with failure to respond to RTX. Patients treated only with RTX with a median follow-up of 62.6 months; 7 of 159 (4.4%) developed ESKD with an estimated renal survival of 97% (95% confidence interval [CI]: 94%-100%) and 95.4% (95% CI: 91.2%-99%) at 5 and 10 years, respectively. CONCLUSION: RTX treatment is associated with excellent long-term renal survival that compares favorably with historical survival rates using the cyclic corticosteroids/cyclophosphamide regimen.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Vargas-Brochero MJ, Lafaut E, Radhakrishnan Y, et al. Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab. Kidney Int Rep. 2025. PMID: 40814621. doi:10.1016/j.ekir.2025.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。